CD-T (C. perfringens C & D + Tetanus)

CD-T vaccine is a fundamental immunization product that provides protection against three distinct clostridial disease conditions: enterotoxemia caused by Clostridium perfringens type C, enterotoxemia caused by Clostridium perfringens type D, and tetanus caused by Clostridium tetani. This combination toxoid vaccine stimulates active immunity against the potent exotoxins produced by these pathogenic organisms, offering essential protection for cattle, sheep, goats, and other susceptible livestock species. The vaccine represents one of the most widely used and economically important biological products in livestock medicine due to the prevalence and severity of the diseases it prevents.

The mechanism of action involves presentation of inactivated bacterial toxins (toxoids) to the animal's immune system, stimulating production of neutralizing antitoxin antibodies without causing disease. Clostridium perfringens types C and D produce epsilon and beta toxins that cause severe intestinal damage and systemic toxicosis, while Clostridium tetani produces tetanospasmin, which causes the characteristic muscle rigidity and spasms of tetanus. By converting these lethal toxins into harmless but immunogenic toxoids through formaldehyde treatment, the vaccine safely induces protective immunity that can neutralize toxins produced during natural infection.

CD-T vaccines are available as aluminum hydroxide-adjuvanted injectable suspensions designed for subcutaneous or intramuscular administration. The adjuvant component enhances immune response by creating a depot effect at the injection site, prolonging antigen exposure and stimulating stronger, longer-lasting immunity. Products are supplied in multi-dose bottles of various sizes ranging from 10 doses to 250 doses, accommodating operations of all scales from small farms to large commercial feedlots and sheep operations. Some formulations include additional clostridial antigens, though the basic CD-T combination remains available as a standalone product.

Regulatory approval for CD-T vaccines covers multiple livestock species including cattle, sheep, and goats, with products licensed by the USDA Center for Veterinary Biologics. These vaccines have established an extensive safety and efficacy record spanning decades of commercial use, with vaccination against Clostridium perfringens and tetanus considered standard of care for sheep and goat operations in particular. Over-the-counter availability makes these products accessible to producers, though veterinary consultation is recommended for designing comprehensive vaccination protocols that address operation-specific disease risks and management constraints.

The primary indication for CD-T vaccine is prevention of enterotoxemia caused by Clostridium perfringens types C and D, commonly known as overeating disease or pulpy kidney disease. Type D enterotoxemia typically affects rapidly growing lambs, kids, and calves on high-concentrate diets, where sudden dietary changes or overconsumption of grain allows explosive Clostridium perfringens proliferation in the intestine with massive epsilon toxin production. Type C enterotoxemia, also called lamb dysentery or hemorrhagic enteritis, primarily affects neonatal lambs and calves, causing severe intestinal hemorrhage and rapid death. Vaccination of pregnant dams and young animals provides critical protection against these frequently fatal diseases.

Tetanus prevention represents the second major indication for CD-T vaccination. Clostridium tetani spores are ubiquitous in soil and enter the body through wounds, surgical sites, or umbilical infections, where anaerobic conditions permit germination and toxin production. Livestock are particularly susceptible to tetanus following castration, tail docking, ear tagging, and other routine management procedures that create potential entry sites for this soil-borne pathogen. Vaccination provides essential protection, especially important for animals undergoing surgical procedures or in environments with high soil spore burdens.

In cattle operations, CD-T vaccination is indicated for calves, replacement heifers, breeding cattle, and feedlot animals at risk for clostridial diseases. Beef calves should be vaccinated as part of routine processing protocols, with particular attention to animals transitioning to high-energy diets during backgrounding or feedlot phases. Dairy calves benefit from vaccination programs that protect against both the immediate risk of neonatal enterotoxemia and the ongoing risk of tetanus associated with management procedures throughout life. Mature cattle require periodic revaccination to maintain immunity, with pre-calving vaccination of pregnant cows enhancing colostral antibody transfer to newborn calves.

Sheep and goat operations represent perhaps the most important application of CD-T vaccination, as these species show particular susceptibility to both enterotoxemia and tetanus. Pregnant ewes and does should receive booster vaccination four to six weeks before parturition to maximize colostral antibody levels for passive protection of newborns. Lambs and kids require active immunization beginning at four to eight weeks of age, depending on maternal vaccination status and colostral antibody levels. Show animals, fiber-producing animals, and breeding stock all benefit from comprehensive CD-T vaccination programs tailored to their specific management and disease risk factors.

Extra-label use of CD-T vaccine in other species may be considered under veterinary guidance, though labeled indications provide the primary basis for product selection. Camelids, cervids, and other ruminant species may benefit from clostridial vaccination using products labeled for sheep and goats, with dosing and protocols adapted based on available research and veterinary experience. The fundamental principles of primary vaccination series followed by annual boosters apply across susceptible species, with modifications based on species-specific immune response characteristics and disease epidemiology.

The standard dosage for CD-T vaccine in cattle is 2 mL administered subcutaneously or intramuscularly, depending on product label specifications. For sheep and goats, the typical dose is also 2 mL, though some products specify 1 mL for small ruminants. Primary vaccination requires two doses administered four to six weeks apart to establish protective immunity, as the initial dose primes the immune system while the booster dose generates the robust antitoxin response necessary for disease protection. Single-dose vaccination provides incomplete protection and should be avoided except in documented previously vaccinated animals receiving annual boosters.

Subcutaneous injection is the preferred administration route for most CD-T vaccine products, with the lateral neck region providing the optimal injection site in both cattle and small ruminants. Subcutaneous administration allows proper antigen presentation to regional lymph nodes while minimizing injection site reactions and potential carcass trim losses. In cattle, injections should be placed in the neck ahead of the shoulder, while in sheep and goats, the axillary region or neck provides appropriate sites. When intramuscular injection is specified or preferred, the neck muscles offer the safest location for all species.

Primary vaccination timing varies by species, age, and production system. In cattle, calves should receive their first CD-T dose at two to four months of age, with the second dose following four to six weeks later at weaning or subsequent processing. Dairy calves raised separately from dams may be vaccinated earlier, with attention to potential maternal antibody interference in calves receiving adequate colostrum. Feedlot cattle of unknown vaccination status should receive a complete two-dose primary series upon arrival, with doses timed according to the expected length of stay and receiving program protocols.

For sheep and goats, pregnant females should receive a booster dose four to six weeks before their expected parturition date to optimize colostral antibody levels. This pre-lambing or pre-kidding vaccination is critical for protecting neonates against type C enterotoxemia during the vulnerable first weeks of life before active immunization is effective. Lambs and kids born to vaccinated dams should receive their first vaccine dose at four to eight weeks of age, while those from unvaccinated dams require earlier vaccination, potentially beginning at one to two weeks of age with additional doses to overcome maternal antibody interference.

Annual revaccination maintains protective immunity throughout the animal's productive life. Breeding cattle should receive boosters pre-breeding or during late gestation to enhance both maternal protection and colostral antibody transfer. Sheep and goats require annual boosters timed to ensure protection during high-risk periods, typically four to six weeks before lambing or kidding for pregnant females. Market animals may receive abbreviated vaccination schedules based on anticipated time to slaughter, though complete vaccination is recommended when production timeline permits.

Withdrawal times for CD-T vaccines are generally minimal, with most products requiring 21 days before slaughter. Specific product labels should be consulted for exact withdrawal periods, as formulations may vary. There are typically no milk discard requirements for dairy cattle, sheep, or goats, though label verification is essential. Proper record keeping of vaccination dates, products used, lot numbers, and withdrawal times supports food safety compliance and quality assurance program requirements.

CD-T vaccines are generally well-tolerated across all labeled species, with the majority of animals experiencing minimal adverse effects following vaccination. The most common side effect is transient injection site swelling, which may vary in severity from barely perceptible to moderately prominent depending on individual animal response, injection technique, and specific product formulation. These localized reactions typically represent normal inflammatory responses to the aluminum hydroxide adjuvant and vaccine antigens, reaching maximum size within 24 to 72 hours and gradually resolving over one to four weeks without intervention.

Systemic reactions following CD-T vaccination include transient fever, decreased appetite, lethargy, and mild depression, typically occurring within 24 hours of administration and resolving within one to two days. These nonspecific signs reflect immune system activation and cytokine release in response to vaccine antigens. Young animals receiving their first vaccination may show more pronounced systemic responses than previously vaccinated adults. Providing adequate nutrition, fresh water, and comfortable resting conditions helps animals recover from these transient effects without complication.

Injection site abscesses occasionally develop following CD-T vaccination, particularly when contaminated equipment introduces bacteria into subcutaneous tissues. These localized infections appear as fluctuant swellings days to weeks after vaccination and may eventually rupture and drain purulent material. Prevention through use of clean needles, proper injection site preparation, and appropriate equipment sanitation minimizes abscess formation. Treatment involves establishing drainage, local wound care, and systemic antimicrobial therapy for severe or persistent infections. Chronic injection site granulomas may persist in some animals even after acute inflammation resolves.

Anaphylactic reactions to CD-T vaccines are rare but represent the most serious potential adverse effect. Signs of anaphylaxis include sudden weakness or collapse, respiratory distress, facial or laryngeal swelling, urticaria, and cardiovascular shock, typically occurring within minutes of vaccine administration. Immediate treatment with epinephrine is potentially life-saving, and producers should have emergency medications readily available during vaccination procedures. Animals experiencing anaphylaxis may require supportive care including intravenous fluids and monitoring for delayed complications.

Species-specific side effect considerations include recognition that sheep and goats may show more pronounced injection site reactions than cattle in some cases, potentially related to their smaller body size and subcutaneous tissue characteristics. Individual animals within any species may demonstrate idiosyncratic responses to specific vaccine formulations, with some products being better tolerated than others in certain populations. Maintaining records of adverse reactions helps identify potential problem products and allows veterinarians to recommend alternative formulations when necessary.

The primary contraindication for CD-T vaccination is a documented history of severe hypersensitivity or anaphylactic reaction to previous doses of clostridial vaccines. Animals that have experienced life-threatening systemic reactions including collapse, severe respiratory distress, or anaphylactic shock following previous vaccination should not receive additional doses of the same product without careful veterinary evaluation. Alternative products from different manufacturers or with different adjuvant systems may be considered in these cases, though cross-reactivity between formulations cannot be excluded and caution is warranted.

Vaccination of acutely ill animals is contraindicated because concurrent disease conditions impair immune response to vaccine antigens and the physiological stress of mounting an immune response may worsen clinical illness. Animals with active infections, severe parasitism, malnutrition, or other debilitating conditions should have vaccination deferred until their health status improves sufficiently to support adequate immune response development. Similarly, severely stressed animals from recent transport, handling, or environmental challenges may benefit from delayed vaccination when circumstances permit.

While CD-T vaccines are generally considered safe for pregnant animals, some caution is warranted regarding vaccination timing. Pre-breeding or early pregnancy vaccination is preferred by some practitioners to avoid any theoretical risk of vaccine-induced complications during critical periods of fetal development. However, pre-parturient vaccination of pregnant ewes, does, and cows is essential for providing colostral protection to neonates and should not be omitted due to pregnancy concerns. The documented benefits of maternal vaccination for neonatal disease prevention substantially outweigh theoretical risks in most situations.

Very young animals present special considerations regarding vaccination timing due to potential interference from maternal antibodies. Neonates with high levels of passively acquired antitoxin may not respond adequately to vaccination, as maternal antibodies neutralize vaccine antigens before they can stimulate active immunity. In calves, lambs, and kids born to well-vaccinated dams, delaying first vaccination until four to eight weeks of age allows sufficient maternal antibody decline to permit active response. Animals born to unvaccinated dams or those that failed to receive adequate colostrum may require earlier vaccination but should receive additional booster doses to ensure immunity.

CD-T vaccine can be administered concurrently with other commonly used livestock vaccines when given at separate injection sites. When multiple vaccines are administered simultaneously, they should be placed at different anatomical locations to allow independent immune response development and facilitate identification of any adverse reactions associated with specific products. Using opposite sides of the neck or maintaining at least four inches of separation between injection sites on the same side provides adequate spacing for cattle, with proportionally adjusted spacing for smaller species.

Combination with other clostridial vaccines is common practice, as many commercial products already combine CD-T antigens with additional clostridial bacterins such as those for blackleg, malignant edema, black disease, and redwater. When using separate products to build comprehensive clostridial protection, simultaneous administration is acceptable, though some practitioners prefer spacing different clostridial products by one to two weeks when schedules permit. The choice between combination products and separate vaccines depends on the specific disease threats present in the operation and the available commercial formulations.

Concurrent administration with modified-live viral vaccines is routine in cattle and sheep operations. Respiratory virus vaccines, clostridial vaccines, and other biological products are commonly given during the same processing event for practical efficiency. Research generally supports acceptable immune responses when these products are administered simultaneously at separate sites, though the inflammatory response to bacterin products may transiently affect concurrent viral vaccine virus replication. Operations with documented suboptimal viral vaccine responses may consider separating administration by one to two weeks.

Immunosuppressive medications including corticosteroids can interfere with immune response development following CD-T vaccination. Animals receiving systemic corticosteroid therapy or other immunosuppressive treatments may not develop adequate antitoxin levels and may require revaccination after drug withdrawal. Long-acting corticosteroid preparations warrant particular attention to timing of subsequent vaccinations. Animals with diseases causing secondary immunosuppression similarly may benefit from revaccination once their underlying condition has resolved and immune function has normalized.

Human safety precautions are essential when handling and administering CD-T vaccines, as accidental self-injection can cause serious tissue reactions and potentially severe complications. Clostridial toxoid products with aluminum hydroxide adjuvants can produce significant local inflammation, abscess formation, and intense pain if accidentally injected into human tissue. All vaccine handlers should exercise extreme care to prevent needle stick injuries by using appropriate restraint equipment, maintaining attention during injection procedures, and never recapping needles. Any person accidentally injected should seek immediate medical attention and inform healthcare providers of the specific product involved.

Vaccine handling and storage precautions are critical for maintaining product efficacy. CD-T vaccines require continuous refrigeration at 35-45°F (2-7°C) and must be protected from freezing, which irreversibly damages vaccine proteins and adjuvant emulsions. During field use, vaccines should be transported in insulated coolers with appropriate ice packs and shielded from direct sunlight and temperature extremes. Multi-dose bottles should be used within the timeframe specified on the product label after first puncture, typically within a few hours, to prevent bacterial contamination and maintain potency of remaining doses.

Food safety precautions include adherence to withdrawal times before slaughter and proper record keeping for all vaccinations administered to food-producing animals. While most CD-T vaccines carry minimal withdrawal requirements, typically 21 days, specific products should be consulted for exact withdrawal periods. Permanent identification of vaccinated animals and documentation of vaccination dates, products, lot numbers, and withdrawal times supports compliance with quality assurance programs and provides necessary records for food safety verification and traceback purposes.

Antimicrobial stewardship considerations, though less directly applicable to vaccines than to therapeutic antimicrobials, relate to the role of vaccination in reducing antimicrobial use in livestock production. Effective vaccination against clostridial diseases eliminates or substantially reduces the need for therapeutic antimicrobial treatment of affected animals, supporting industry commitments to responsible antimicrobial stewardship. Given that clostridial diseases are often rapidly fatal with limited treatment success, prevention through vaccination represents the primary control strategy and a key component of antimicrobial reduction efforts.

Environmental and disposal precautions include proper handling of unused vaccine, spent containers, and used needles and syringes. Expired or compromised vaccines should be disposed of according to label directions and applicable local regulations. Empty vaccine bottles should be rinsed before disposal to remove residual vaccine material. All sharps must be collected in puncture-resistant containers and disposed of through appropriate channels to protect handlers, sanitation workers, and the environment from needle stick injuries and potential contamination.

CD-T vaccines require refrigerated storage at temperatures between 35°F and 45°F (2°C to 7°C) from manufacturing through administration to maintain full potency and efficacy. This cold chain requirement applies throughout product distribution and on-farm storage, with any breaks in temperature control potentially compromising vaccine immunogenicity. Vaccines should be stored in dedicated refrigerators with accurate temperature monitoring, positioned on middle shelves away from cooling elements that might cause localized freezing. Regular temperature documentation supports quality assurance requirements and provides evidence of proper storage conditions.

Protection from freezing is absolutely critical, as ice crystal formation permanently damages vaccine proteins and disrupts the aluminum hydroxide adjuvant matrix essential for proper immune stimulation. Frozen vaccines must be discarded even if subsequently thawed, as there is no reliable method to assess whether freezing damage has occurred. During transport to pasture or processing sites, vaccines should be packed in insulated coolers with refrigerant packs arranged to maintain temperature without direct contact that could cause localized freezing. Winter transport requires particular attention to prevent freezing during cold weather.

Multi-dose bottle handling requires careful attention to aseptic technique to prevent contamination of vaccine contents and maintain sterility for subsequent doses. A sterile transfer needle should be used for withdrawing doses rather than repeated insertion of the administration needle. Vaccine bottles should be thoroughly shaken before each dose withdrawal to ensure uniform suspension of adjuvant and antigens. Once opened, multi-dose bottles should be used within the timeframe specified on the label, typically two to four hours under field conditions, after which remaining vaccine should be discarded regardless of apparent volume remaining.

Disposal protocols for vaccines, containers, and associated equipment should follow label directions and local regulations. Expired or temperature-compromised vaccines should be disposed of appropriately, which may include inactivation before disposal in some jurisdictions. Empty vaccine bottles should be triple-rinsed with water and disposed of according to label specifications. Used needles, syringes, and other sharps must be collected in designated puncture-resistant containers and disposed of through proper biohazard waste channels to prevent needle stick injuries and ensure appropriate handling of potentially contaminated materials.

All cattle breeds are susceptible to Clostridium perfringens enterotoxemia and tetanus, with vaccination recommended regardless of breed type. However, certain management factors associated with different cattle breeds and production systems may influence disease risk and vaccination timing. Beef breeds managed on extensive pasture systems may have different exposure patterns than dairy breeds in intensive management, though both require comprehensive vaccination programs. Rapidly growing cattle of any breed transitioning to high-concentrate diets face elevated enterotoxemia risk during the dietary adaptation period.

Dairy cattle considerations include the integration of CD-T vaccination into heifer development programs and dry cow management protocols. Dairy replacements should complete their primary vaccination series before entering the milking herd, with annual boosters coordinated with dry-off periods or other routine processing events. The continuous calving patterns typical of dairy operations require systematic vaccination protocols to ensure all animals maintain current immunity. Dairy calves raised in intensive hutch or group housing systems may face different tetanus exposure risks than pasture-raised beef calves, influencing vaccination timing decisions.

Sheep breed considerations are particularly important for CD-T vaccination, as this vaccine combination is considered essential for all sheep operations regardless of production type. Fine wool breeds, meat breeds, hair sheep, and dairy sheep all require comprehensive vaccination against these clostridial diseases. Lambing intensity and management system influence disease risk, with accelerated lambing programs and intensive feeding operations facing potentially higher enterotoxemia pressure. Breed-specific show requirements may include documented vaccination status, making program compliance important for exhibition animals.

Goat breeds across all production types—dairy, meat, fiber, and companion animals—require CD-T vaccination as a foundation of preventive health programs. The diverse management systems applied to different goat breeds, from intensive dairy operations to extensive meat goat production, all include potential exposure to Clostridium perfringens and Clostridium tetani. Kid management practices including disbudding and castration create tetanus risk regardless of breed, emphasizing the importance of both maternal vaccination for colostral protection and timely active immunization of young animals.

Multivalent clostridial vaccines containing CD-T components combined with additional antigens represent the most commonly used alternatives to standalone CD-T products. Seven-way and eight-way clostridial vaccines provide comprehensive protection against Clostridium chauvoei (blackleg), C. septicum, C. novyi, C. sordellii, and C. haemolyticum in addition to C. perfringens types C and D and tetanus. These combination products offer convenient, cost-effective protection against the full spectrum of clostridial diseases with a single injection series, making them the preferred choice for cattle operations facing multiple clostridial disease threats.

Tetanus antitoxin provides immediate passive immunity for animals at imminent risk of tetanus, such as those with contaminated wounds or those undergoing emergency surgical procedures without adequate vaccination history. Unlike the active immunity provided by CD-T toxoid vaccination, tetanus antitoxin provides temporary protection through preformed antibodies that decline over approximately two to three weeks. Tetanus antitoxin may be administered concurrently with CD-T vaccine to provide both immediate and long-term protection, with the antitoxin covering the vulnerable period before active immunity develops.

Clostridium perfringens type A toxoid vaccines are available for situations where type A enterotoxemia is a specific concern. While standard CD-T vaccines protect against types C and D, type A Clostridium perfringens produces different toxins associated with distinct disease syndromes in some animal populations. Combination products including type A protection are available from some manufacturers and may be recommended in operations with documented type A disease history. Veterinary consultation helps determine whether type A vaccination is warranted based on specific herd disease patterns and regional epidemiology.